Shares of MEDNAX Inc (NYSE:MD) have been given a consensus rating of “Hold” by the sixteen ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $54.31.

Several brokerages have recently weighed in on MD. Zacks Investment Research lowered shares of MEDNAX from a “hold” rating to a “sell” rating in a research report on Friday, July 20th. Citigroup dropped their price objective on shares of MEDNAX from $57.00 to $50.00 and set a “neutral” rating on the stock in a research report on Friday, May 4th. Leerink Swann began coverage on shares of MEDNAX in a research report on Thursday, July 12th. They issued a “market perform” rating and a $50.00 price objective on the stock. ValuEngine raised shares of MEDNAX from a “strong sell” rating to a “sell” rating in a research report on Friday, August 3rd. Finally, Stifel Nicolaus set a $47.00 price objective on shares of MEDNAX and gave the company a “hold” rating in a research report on Thursday, August 2nd.

In other MEDNAX news, insider John C. Pepia sold 3,500 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $48.18, for a total value of $168,630.00. Following the transaction, the insider now directly owns 30,148 shares of the company’s stock, valued at approximately $1,452,530.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Dominic J. Andreano sold 18,000 shares of the firm’s stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $46.95, for a total transaction of $845,100.00. Following the completion of the transaction, the senior vice president now directly owns 24,896 shares in the company, valued at $1,168,867.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 75,751 shares of company stock worth $3,491,724. 2.40% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in MD. Pzena Investment Management LLC increased its holdings in MEDNAX by 134.8% in the 1st quarter. Pzena Investment Management LLC now owns 2,258,712 shares of the company’s stock valued at $125,652,000 after buying an additional 1,296,682 shares during the period. Orbimed Advisors LLC increased its holdings in MEDNAX by 133.1% in the 2nd quarter. Orbimed Advisors LLC now owns 862,600 shares of the company’s stock valued at $37,333,000 after buying an additional 492,600 shares during the period. MUFG Securities EMEA plc increased its holdings in MEDNAX by 217.5% in the 1st quarter. MUFG Securities EMEA plc now owns 667,600 shares of the company’s stock valued at $37,139,000 after buying an additional 457,300 shares during the period. BNP Paribas Arbitrage SA increased its holdings in MEDNAX by 1,468.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 466,496 shares of the company’s stock valued at $25,951,000 after buying an additional 436,752 shares during the period. Finally, Cooke & Bieler LP increased its holdings in MEDNAX by 150.5% in the 2nd quarter. Cooke & Bieler LP now owns 670,185 shares of the company’s stock valued at $29,006,000 after buying an additional 402,690 shares during the period. 96.34% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MD opened at $46.83 on Tuesday. The stock has a market capitalization of $4.41 billion, a PE ratio of 14.87, a P/E/G ratio of 1.27 and a beta of 0.19. MEDNAX has a fifty-two week low of $40.56 and a fifty-two week high of $63.04. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.52 and a current ratio of 1.52.

MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, August 2nd. The company reported $1.07 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.07. The company had revenue of $915.90 million for the quarter, compared to analyst estimates of $911.77 million. MEDNAX had a net margin of 9.59% and a return on equity of 10.42%. The company’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.85 earnings per share. equities research analysts anticipate that MEDNAX will post 3.71 EPS for the current fiscal year.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

See Also: Investing in Dividend Stocks

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.